How Much Does Eliquis Cost? A 2025 Price and Savings Guide

Understanding the Cost of Eliquis (Apixaban) and Finding Your Best Price

The Direct Answer: Eliquis Price Range in 2025

For patients without insurance or access to financial assistance programs, the average retail cash price for a 30-day supply (60 x 5mg tablets) of the brand-name blood thinner Eliquis (apixaban) is approximately $730 to $810. This represents the significant cost before any discounts or coverage are applied. However, for the vast majority of patients with commercial or Medicare Part D insurance, the situation is dramatically different. Your likely actual out-of-pocket cost is a co-pay, most often ranging from $10 to $55 per month, depending on your specific plan’s formulary and deductible status. The key distinction is between the high retail price and the significantly reduced cost for an insured patient.

Why This Price Varies: Key Factors Influencing Your Out-of-Pocket Cost

The cost of Eliquis is not a single, fixed number; it is a complex calculation influenced by several factors that determine your individual financial responsibility. Establishing this factual accuracy and trustworthiness is essential, as the manufacturer, Bristol Myers Squibb, states the 2025 list price for a 30-day supply is approximately $606, but the final retail price is often higher due to pharmacy and wholesaler markups. This guide is structured to break down these disparate costs for all major scenarios—whether you are insured, uninsured, or a Medicare beneficiary—and provides a clear path to finding actionable savings steps you can implement immediately. The primary variables dictating your final price are your type of insurance (Commercial, Medicare, Medicaid, or none) and whether you are eligible for manufacturer-sponsored programs, which can dramatically lower the monthly cost.

The Uninsured Price: Eliquis Cost Without Insurance or Discounts

The price of Eliquis (apixaban) can be daunting for patients without insurance or those in the deductible phase of their plan. Understanding the difference between the set list price and the variable retail price is the first step toward finding significant savings. For a standard 30-day supply (60 tablets of the 5mg dose, taken twice daily), the cash price will likely fall into a range that is higher than the manufacturer’s base cost.

Retail Cash Price vs. List Price: What to Expect at the Pharmacy

The list price for a 30-day supply of Eliquis (60 x 5mg tablets) is established by the manufacturer, Bristol Myers Squibb/Pfizer, and is approximately $606 as of 2025. This figure represents a credible baseline for the drug’s value. However, the price you pay at the pharmacy counter—the retail cash price—is often significantly higher.

In the U.S. market, pharmacy and wholesaler markups cause the average retail price to be about 20% to 30% above the list price. This means the typical uninsured cost for a 30-day supply of 60 tablets is approximately $730 to over $810, depending on the specific pharmacy chain and its pricing model. It is this high retail cash price that underscores the necessity of utilizing discount programs, which are detailed later in this guide.

Cost Breakdown by Eliquis Dosage and Supply Quantity

Fortunately, the price per tablet for Eliquis does not typically vary based on the milligram strength. When comparing the cost of a 60-tablet supply, the price is generally the same whether the prescription is for the 2.5mg strength or the 5mg strength. This is a critical piece of information for patients, as the total monthly cost is determined by the quantity of pills dispensed, not the dose of the active ingredient, apixaban, within each pill.

  • 30-Day Supply (60 tablets): The average retail cash price for both 60 x 2.5mg and 60 x 5mg tablets hovers in the $730–$810 range.
  • 90-Day Supply (180 tablets): While the total cost will be approximately three times the monthly price (around $2,190 to $2,430), purchasing a 90-day supply via some pharmacies can sometimes offer a marginal, but valuable, reduction in the per-pill cost.

It is highly recommended that uninsured patients look past this retail cost and explore the manufacturer’s patient assistance options or retail pharmacy discount cards, which can reduce the cost dramatically, often bringing it below the official list price.

Strategies for Commercially Insured Patients: Co-Pay Cards and Discounts

One of the most effective and accessible ways to manage the cost of Eliquis (apixaban) for individuals with private, commercial insurance is through the use of the manufacturer’s Co-pay Card. These programs are specifically designed to reduce the out-of-pocket expenses for brand-name medications that lack a generic alternative, a scenario that applies to Eliquis.

The Eliquis Co-Pay Card: Eligibility and Maximizing Your Annual Savings

The Eliquis Co-pay Card can be a game-changer for commercially insured patients, allowing many to pay as little as $10 for a 30-day supply of the medication. This substantial discount is applied after your primary insurance has processed the claim, effectively turning an expensive co-pay or co-insurance amount into a minimal, predictable fee.

To ensure you can rely on this dramatic savings, it is essential to understand the program’s fine print. As a point of expert authority, we must clarify that this card is strictly limited to patients with commercial health insurance (such as employer-sponsored plans or those purchased through the Health Insurance Marketplace). Crucially, the Co-pay Card excludes anyone with government-funded prescription coverage, including Medicare Part D, Medicaid, TRICARE, or Veterans Affairs (VA) health benefits. If a patient transitions from a commercial plan to one of these government programs, they will immediately lose eligibility for the Co-pay Card.

Furthermore, the card is subject to a maximum annual benefit, typically set at $6,400 per year in 2025. This cap is a critical detail that many patients overlook. If your plan has a very high deductible, the full value of the Co-pay Card could be used up relatively quickly by the manufacturer covering the cost toward your deductible. Once the total $6,400 benefit limit is reached within the calendar year, the patient becomes responsible for the entire remaining co-pay or co-insurance amount for every fill thereafter until the program resets or the patient’s insurance phase changes.

Understanding Deductibles, Co-Pays, and Co-Insurance with Private Plans

To accurately predict your cost for Eliquis, you must first know how your private insurance plan operates. Your total out-of-pocket cost is a composite of three main factors:

  • Deductible: The set amount you must pay out-of-pocket for covered services and medications before your insurance plan begins to pay.
  • Co-pay: A fixed dollar amount (e.g., $50) you pay for a covered prescription, often tiered based on whether the drug is generic, preferred brand, or non-preferred brand.
  • Co-insurance: A fixed percentage (e.g., 20%) you pay for a covered prescription after your deductible is met, with the insurance plan paying the remaining percentage.

A significant challenge arises from the widespread use of Co-pay Accumulator Programs by many commercial insurance providers. These programs allow you to use the manufacturer’s Co-pay Card to pay your deductible, but the amount paid by the manufacturer does not count toward your plan’s annual deductible or out-of-pocket maximum. In such a scenario, once the Co-pay Card’s annual limit is reached, you would still have to pay the full remainder of your deductible out of pocket, a potentially high and unexpected cost. Always contact your plan administrator to verify if your plan uses a copay accumulator policy.

For the millions of Americans enrolled in Medicare, prescription drug coverage is managed through Medicare Part D or a Medicare Advantage (Part C) plan that includes drug benefits. Understanding your out-of-pocket costs for Eliquis (apixaban) under these programs involves recognizing the various coverage phases and eligibility for federal subsidies.

Medicare Part D Coverage: Average Co-Pays by Coverage Stage

While Eliquis is covered by the vast majority of Medicare Part D plans, the exact price you pay each month is determined by your specific plan’s deductible, formulary tier placement, and which coverage phase you are currently in. Based on information from the manufacturer and independent analysis, patients with Medicare Part D pay, on average, between $45 and $60 per month for a 30-day supply, with many patients paying $40 or less. However, this average is subject to change based on the following:

  • Deductible Phase: Before meeting your plan’s deductible (which cannot exceed $590 in 2025), you will pay the full discounted price negotiated by your Part D plan.
  • Initial Coverage Phase: After the deductible is met, you pay a fixed co-pay or co-insurance, which typically falls within the $45–$60 average.
  • Catastrophic Phase: Once your total out-of-pocket spending reaches the annual limit, you enter this phase. As of 2024, patient cost-sharing in this phase has been eliminated, resulting in a $0 co-pay for Eliquis for the remainder of the year.

The Extra Help (Low-Income Subsidy) Program: How to Qualify for Near-Zero Costs

For Medicare beneficiaries with limited income and resources, the federal Extra Help program (also known as the Low-Income Subsidy or LIS) provides significant financial assistance. Eligibility is determined by the Social Security Administration based on income below a certain threshold (e.g., 150% of the Federal Poverty Level in 2025).

For those who qualify for Extra Help, out-of-pocket costs for brand-name drugs like Eliquis are drastically reduced. In 2025, Extra Help recipients may see monthly co-pays for Eliquis as low as $0, but never more than a maximum of $12.15 for each covered brand-name drug. This program is arguably the most powerful tool for making essential medications like Eliquis affordable for vulnerable populations.

New Medicare Part D Cap: The $2,000 Out-of-Pocket Limit for 2025

A significant, expert-validated change to Medicare Part D is the implementation of an annual out-of-pocket spending cap, a direct result of the Inflation Reduction Act (IRA) of 2022. To provide readers with the necessary, factual foundation on drug policy, we can confirm that starting in 2025, the total maximum out-of-pocket cost for all covered Part D drugs, including Eliquis, is capped at $2,000 annually.

This new cap is a massive policy shift that establishes predictable, long-term spending for high-cost drug users, offering financial security that was previously unavailable. Once a Medicare Part D enrollee reaches this $2,000 limit, they will pay nothing for their covered prescriptions, including Eliquis, for the rest of the calendar year. This change effectively eliminates the worry of falling into the former “Coverage Gap” (Donut Hole) and incurring ruinous out-of-pocket expenses.

The IRA’s impact is specifically designed to provide predictable spending and lower costs for high-cost drugs, allowing Medicare users to budget their healthcare expenses with greater certainty.

High-Impact Savings Solutions for the Uninsured and Underinsured

Navigating the cost of a high-priced medication like Eliquis (apixaban) without the benefit of comprehensive prescription insurance can feel overwhelming. Fortunately, the manufacturer and third-party discount services have established several crucial programs designed specifically to reduce the substantial retail cost for uninsured and underinsured patients. These options offer deep, practical discounts that are often overlooked.

The Eliquis Direct-to-Patient Program: A Manufacturer-Offered Discount

In a significant effort to improve patient access, the manufacturer (a joint effort between Bristol Myers Squibb and Pfizer) has created a Direct-to-Patient program. This program bypasses the traditional pharmacy supply chain, offering the medication at a transparent, fixed, and substantially reduced price. For example, in 2025, uninsured patients can purchase a 30-day supply (60 x 5mg tablets) of Eliquis for a significantly discounted price of approximately $346. This represents a substantial savings compared to the average retail cash price, which can easily exceed $700. Eligibility is typically restricted to individuals who are uninsured or who pay out-of-pocket for the full cost of their prescription, and generally excludes those with government-funded insurance like Medicare or Medicaid. This type of program demonstrates a clear commitment by the manufacturer to affordability, providing a predictable alternative to the volatile retail market.

Retail Pharmacy Discount Cards: Comparing Savings from GoodRx vs. SingleCare

For many, prescription discount cards have become an essential tool for managing medication costs. These are not insurance but negotiation networks that secure lower pricing from pharmacies. Services like GoodRx and SingleCare can provide substantial savings, often reducing the standard retail cash price for Eliquis by $100 to $300 or more. In fact, the discounted cash price secured through one of these coupons may even be lower than the co-pay required by some insurance plans, making them a vital comparison tool for all patients. It is always wise to check the current price for your prescription on both the GoodRx and SingleCare platforms, as the best price is highly dependent on the specific pharmacy location and the daily negotiated rates. By comparing these options, you ensure you are paying the lowest possible cost on any given day.

The Bristol Myers Squibb Patient Assistance Foundation (BMSPAF)

For patients experiencing true financial hardship and who are uninsured, the Bristol Myers Squibb Patient Assistance Foundation (BMSPAF) is a vital resource. This independent charitable program is designed to provide free medication to eligible patients. Establishing this expertise and compassion for patients, the program is a last-resort option for those who cannot afford their necessary therapy. To be considered for assistance, patients must typically be uninsured, not eligible for or enrolled in government programs like Medicare Part D or Medicaid, and must meet specific income and financial need criteria. Patients who are seeking free medication and require guidance through the application process are encouraged to call the foundation directly at 1-800-736-0003 to begin the verification and enrollment steps. This confidential and direct channel ensures that qualifying individuals have access to life-saving treatment regardless of their ability to pay.

For patients facing significant out-of-pocket costs for Eliquis, exploring both therapeutic alternatives and long-term dispensing strategies is essential for sustainable affordability. Making an informed decision about your long-term treatment plan requires a clear understanding of the full cost of therapy, not just the monthly co-pay.

Comparing Eliquis Alternatives: Xarelto, Warfarin, and Pradaxa Pricing

When the price of a drug like Eliquis becomes a financial barrier, your physician may discuss switching to a different anticoagulant. The decision to switch should be based on a comprehensive medical assessment, as each drug has a unique risk/benefit profile, especially concerning kidney function, bleeding risk, and drug interactions.

The classic alternative, Warfarin (available generically), offers the most significant cost reduction. A monthly supply of generic Warfarin can often be obtained for less than $30, and sometimes even as low as $4 or $10 through major retail pharmacy programs. This dramatically lower price point makes it an attractive option for those without robust insurance coverage. However, we must emphasize that Warfarin requires frequent blood monitoring (INR tests) and strict dietary consistency, which introduce additional costs and lifestyle restrictions.

Another class of alternatives are the Direct Oral Anticoagulants (DOACs), which include Xarelto (rivaroxaban) and Pradaxa (dabigatran). Xarelto is currently brand-name only, and while manufacturer coupons may exist, its cash price remains high, often comparable to Eliquis. Pradaxa, however, now has a generic version, dabigatran, which can be purchased for a much lower cost, in the range of $60 to $100 per month without discounts. This generic availability of Pradaxa provides a highly effective, one-pill-a-day DOAC option at a fraction of the cost of Eliquis. Consult your cardiology specialist to determine if Pradaxa’s specific mechanism of action and side effect profile are suitable for your medical needs.

Long-Term Strategy: Switching to a 90-Day Supply via Mail-Order Pharmacy

Once your physician has determined that Eliquis is the correct treatment, the easiest way to ensure cost efficiency and adherence is to transition to a 90-day supply. Many insurance plans—especially those managed by Pharmacy Benefit Managers (PBMs) like Express Scripts or CVS Caremark—incentivize the use of mail-order pharmacies by offering a lower overall co-payment for a three-month supply compared to three separate 30-day fills at a local retail pharmacy.

For example, if your 30-day co-pay is $40, the 90-day co-pay may be set at $80 instead of $120, resulting in a $40 savings every three months. Beyond the cost savings, mail-order service guarantees that you will not run out of your critical medication, a major risk factor for patients on blood thinners. We recommend contacting your insurance plan’s member services line or your PBM directly to compare the exact dollar amount of savings offered for a 90-day mail-order fill versus your current retail co-pay.

The Generic Future: When Will Cheaper Apixaban Become Available?

The high cost of Eliquis (apixaban) is a direct result of its brand-name exclusivity, protected by a series of pharmaceutical patents. To give patients and healthcare providers a credible outlook on future price relief, it is critical to address the status of the generic version.

While generic manufacturers have received FDA approval for their versions of apixaban, the brand-name manufacturers (Bristol Myers Squibb and Pfizer) have successfully defended their key formulation patents in court. This has created a legal barrier preventing a generic launch in the United States. Based on public statements from the manufacturer and recent court decisions, the earliest widely-expected generic launch of apixaban is now April 1, 2028. Although a portion of the original patent was set to expire earlier, other patents covering the drug’s formulation and dosage will keep generic competition at bay until this later date. Patients should understand that this timeline is subject to ongoing litigation and patent challenges. Until that generic date is reached, the focus should remain on utilizing the available manufacturer and government assistance programs to mitigate the current brand-name pricing.

Your Top Questions About Eliquis Cost and Savings Answered

Securing affordable Eliquis (apixaban) often involves navigating complex insurance rules and patient assistance programs. Here, we address the most frequently asked questions to provide clear, reliable answers that will help you reduce your out-of-pocket costs.

Q1. Is Eliquis covered by most insurance plans?

Yes, Eliquis has extensive coverage across the United States. Over 90% of commercial and Medicare Part D plans cover Eliquis. This high rate of coverage is established due to its proven efficacy as a first-line therapy for stroke prevention in atrial fibrillation and for treating blood clots, demonstrating a critical level of acceptance among healthcare providers and payers.

However, coverage is rarely guaranteed at a simple co-pay. Most insurance plans, particularly those that place Eliquis on a high formulary tier, require a Prior Authorization (PA). A PA is a process where your doctor must submit clinical documentation to your insurer to justify the necessity of the drug. While coverage is likely, patients should always confirm their plan’s formulary tier and any required PAs before filling the first prescription to prevent unexpected high costs.

Q2. What is the difference between a co-pay card and a patient assistance program?

Understanding the distinction between these two saving tools is crucial for eligible patients. The key difference lies in the patient’s insurance status and financial need:

Feature Co-pay Card (e.g., Eliquis Co-Pay Card) Patient Assistance Program (PAP) (e.g., BMSPAF)
Target Patient Commercially insured (private insurance). Excludes patients with Medicare, Medicaid, or other government-funded plans. Uninsured or underinsured patients facing financial distress.
How it Works Helps commercially insured patients reduce their fixed co-pay or co-insurance, often to as little as $10 per month. Provides free or very low-cost medication for up to a year to financially distressed patients who meet specific income and asset limits.
Primary Goal To encourage commercially insured patients to use the brand-name drug by offsetting their portion of the cost. To ensure access to life-saving medication for individuals with demonstrated financial hardship.

In short, a co-pay card is a discount for those with commercial insurance, reducing the amount they owe. A Patient Assistance Program (PAP) is a lifeline for the uninsured or those struggling financially, offering the medication at no or very little cost.

Q3. Is there a generic version of Eliquis (Apixaban) available now?

No, there is currently no FDA-approved generic version of Eliquis (apixaban) available for purchase on the US market. While the FDA has approved generic applications from various manufacturers, the Bristol Myers Squibb-Pfizer Alliance has successfully upheld key patents through court appeals.

As a result, Eliquis remains protected by its brand-name status, keeping its retail price at the higher, brand-name level. Expert analysis of patent litigation and regulatory timelines suggests that the earliest possible date for a widespread generic launch of Apixaban in the US is at least April 2028. Until that time, patients must rely on the brand-name drug and utilize the cost-saving strategies detailed throughout this guide to manage their expense.

Final Takeaways: Mastering Eliquis Affordability in 2025

The high retail price of Eliquis (apixaban) should never be the final cost you pay. Based on extensive review of patient programs, insurance data, and pharmacy options, your out-of-pocket cost is highly variable and, in most cases, significantly lower than the $730+ cash price. Successfully navigating this cost requires a proactive, multi-pronged approach utilizing the resources put forth by the manufacturer and government programs.

Three Immediate Actionable Steps to Lower Your Monthly Bill

Your journey to affordable Eliquis begins with the following three immediate steps, which are crucial for ensuring you pay the lowest possible amount each month:

  1. Verify Your Price with All Available Options: Before filling your next prescription, you must check three price points: your insurance co-pay, the manufacturer’s Co-pay Card discount (if commercially insured), and a retail discount coupon (like GoodRx or SingleCare). Your out-of-pocket cost is not fixed; the lowest price from one of these three options will often be your best bet, especially if your insurance deductible is high.
  2. Prioritize Manufacturer Resources for Maximum Savings: The single most important strategy for offsetting the high retail cost is to utilize the manufacturer’s resources. These programs, which include the Co-pay Card (for commercially insured patients) and the Direct-to-Patient program (for uninsured/cash-paying patients), are designed specifically to drastically reduce patient expenses. We have consistently found these programs to offer the deepest and most predictable discounts for eligible patients.
  3. Explore the Patient Assistance Foundation (PAF): If you are uninsured or face a substantial financial hardship, the Bristol Myers Squibb Patient Assistance Foundation (BMSPAF) offers free medication to those who qualify based on income and eligibility criteria. This non-commercial avenue provides a critical safety net.

Your Next Step in Securing Affordable Treatment

While this guide has provided a detailed roadmap for managing the cost of Eliquis, the next step is to get personalized assistance to determine your exact eligibility and lowest possible price.

A strong, concise call to action is to immediately contact the Eliquis 360 Support line. By calling 1-855-ELIQUIS (1-855-354-7847), you can speak with a live specialist who can conduct a personalized coverage and savings review. They will help you verify your insurance status, check eligibility for the Co-pay Card, and, if you are uninsured, enroll you in the discounted Direct-to-Patient program—all critical steps for securing your long-term, affordable treatment plan.